Zydelig®▼ (idelalisib)

Updated advice following conclusion of a safety review

 

 

Julian Cole, MA, MRCPI, Dip Pharm Med, FFPM, the UK & Ireland Medical Director at Gilead Sciences provides an overview of the outcome of an EU-wide review of Zydelig (idelalisib) in the treatment of chronic lymphocytic leaukaemia (CLL) and follicular lymphoma (FL).

This update was released on the 27th of July, 2016, in agreement with the European Medicines Agency (EMA), the UK Medicines and Healthcare Products Regulatory Agency (MHRA), and the Health Products Regulatory Authority (HPRA).

 

For full details, please follow the links below:

United Kingdom

Republic of Ireland

 

This programme has been supported and developed by Gilead Sciences Ltd.

ZDG/UK/16-10/MM/1899, October 2016